共 11 条
[11]
SANDERS DB, 2003, IN PRESS ANN NY ACAD
Mycophenolate mofetil for myasthenia gravis - An analysis of efficacy, safety, and tolerability
被引：92
作者：
Meriggioli, MN
Ciafaloni, E
Al-Hayk, KA
Rowin, J
Tucker-Lipscomb, B
Massey, JM
Sanders, DB
机构：
[1] Rush Univ, Dept Neurol Sci, Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA
[2] Univ Rochester, Sch Med, Dept Neurol, Rochester, NY 14627 USA
[3] Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA
来源：
关键词：
D O I：
10.1212/01.WNL.0000094122.88929.0B
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The authors report a retrospective analysis of the use of mycophenolate mofetil (MyM) in 85 patients with autoimmune myasthenia gravis. The Myasthenia Gravis Foundation of America ( MGFA) postintervention status ( PIS) was used to characterize the treatment response in each patient. Sixty-two patients (73%) achieved a PIS status indicating improvement. Quantitative strength testing performed on the majority of patients before and after treatment also improved. Side effects to MyM were observed in 27% of patients but required discontinuation in only 6%.
引用
收藏
页码：1438 / 1440
页数：3
相关论文